Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
复制标题
18F-3-氟-3-脱氧-L-胸苷对非小细胞肺癌的分期和再分期有用吗？
作者：
D. Cobben;P. Elsinga;H. Hoekstra;A. Suurmeijer;W. Vaalburg;B. Maas;P. L. Jager;H. Groen
未标记
本研究的目的是比较非小细胞肺癌（NSCLC）患者的18 F-3 '-氟-3'-脱氧-L-胸苷（FLT）PET与临床TNM分期（包括18 F-FDG PET）。
方法
NSCLC患者接受了全身18 F-FDG PET和全身18 F-FLT PET，使用中位数为360 MBq的18 F-FDG（范围，160-500 MBq）和中位数为210 MBq的18 F-FLT（范围，130-420 MBq）。注射18F-FDG后90 min进行18F-FDG PET，注射18F-FLT后60 min进行18F-FLT PET。两名观察者独立分类所有病变的示踪剂摄取的定位和强度。比较了所有18F-FDG PET和18F-FLT PET病变。根据病史、体格检查、支气管镜检查、CT和18F-FDG PET结果，将18F-FLT PET分期与临床TNM分期进行比较。从8例患者中，计算标准化摄取值（SUV）。计算最大SUV和平均SUV。
结果
研究了16例IB-IV期NSCLC患者和1例强烈怀疑NSCLC的患者。使用18 F-FDG PET作为参考标准，8例在18 F-FLT PET前接受治疗的患者的逐病灶敏感性为80%，9例未接受预治疗的患者的敏感性为27%。与临床TNM分期相比，18 F-FLT PET分期对17例患者中的8例患者是正确的：既往治疗组9例患者中的5例，既往未治疗组8例患者中的3例。18F-FLT PET的最大SUV（中位数为2.7，范围为0.8-4.5）显著低于18F-FDG PET（中位数为8.0，范围为3.7-18.8）（n = 8; P = 0.012）。18F-FLT PET的平均SUV（中位数为2.7，范围为1.4-3.3）显著低于18F-FDG PET（中位数为6.2，范围为2.8-13.9）（n = 6; P = 0.027）。
结论
18F-FLT PET对NSCLC的分期和再分期无效。
UNLABELLED
The objective of this study was to compare 18F-3'-fluoro-3'-deoxy-L-thymidine (FLT) PET with clinical TNM staging, including that by 18F-FDG PET, in patients with non-small cell lung cancer (NSCLC).
METHODS
Patients with NSCLC underwent whole-body 18F-FDG PET and whole-body 18F-FLT PET, using a median of 360 MBq of 18F-FDG (range, 160-500 MBq) and a median of 210 MBq of 18F-FLT (range, 130-420 MBq). 18F-FDG PET was performed 90 min after 18F-FDG injection, and 18F-FLT PET was performed 60 min after 18F-FLT injection. Two viewers independently categorized the localization and intensity of tracer uptake for all lesions. All 18F-FDG PET and 18F-FLT PET lesions were compared. Staging with 18F-FLT PET was compared with clinical TNM staging based on the findings of history, physical examination, bronchoscopy, CT, and 18F-FDG PET. From 8 patients, standardized uptake values (SUVs) were calculated. Maximal SUV and mean SUV were calculated.
RESULTS
Sixteen patients with stage IB-IV NSCLC and 1 patient with strong suspicion of NSCLC were investigated. Sensitivity on a lesion-by-lesion basis was 80% for the 8 patients who received treatment before 18F-FLT PET and 27% for the 9 patients who did not receive pretreatment, using 18F-FDG PET as the reference standard. Compared with clinical TNM staging, staging by 18F-FLT PET was correct for 8 of 17 patients: 5 of 9 patients in the group with previous therapy and 3 of 8 patients in the group without previous therapy. The maximal SUV of 18F-FLT PET, at a median of 2.7 and range of 0.8-4.5, was significantly lower than that of 18F-FDG PET, which had a median of 8.0 and range of 3.7-18.8 (n = 8; P = 0.012). The mean SUV of 18F-FLT PET, at a median of 2.7 and range of 1.4-3.3, was significantly lower than that of 18F-FDG PET, which had a median of 6.2 and range of 2.8-13.9 (n = 6; P = 0.027).
CONCLUSION
18F-FLT PET is not useful for staging and restaging NSCLC.
DOI：
10.1016/s0021-9258(18)68484-4
发表时间：
1988-06
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
J L Sherley;T J Kelly
通讯作者：
J L Sherley;T J Kelly
E-钙粘蛋白/p120-连环蛋白的连接与出生后小鼠耳蜗中支持细胞向毛细胞转化的缺乏相关
影响因子：
4.8
作者：
Luo WW;Wang XW;Ma R;Chi FL;Chen P;Cong N;Gu YY;Ren DD;Yang JM
通讯作者：
Yang JM